The PROTAC molecule required for the treatment would be designed to have a NRF2-binding element and a CRBN ligand, whose efficacy in NRF2 degradation has been previously demonstrated in NSCLC models [197]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.